These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12846596)

  • 1. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
    Groenendaal-van de Meent D; Adel MD; Noukens J; Rijnders S; Krebs-Brown A; Mateva L; Alexiev A; Schaddelee M
    Clin Drug Investig; 2016 Sep; 36(9):743-751. PubMed ID: 27352308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment.
    Frost CE; Ly V; Garonzik SM
    Drugs R D; 2021 Dec; 21(4):375-384. PubMed ID: 34363188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants.
    Fan B; Dai D; Cohen M; Xu H; Yin F; Nagaraja R; Mobilia M; Almon C; Basile FG; Yang H
    Clin Pharmacol Drug Dev; 2021 Jan; 10(1):99-109. PubMed ID: 32648303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
    Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
    Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment.
    Heinig R; Lambelet M; Nagelschmitz J; Alatrach A; Halabi A
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):619-628. PubMed ID: 30825073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
    Chavan A; Burke L; Sawant R; Navarro-Gonzales P; Vargo D; Paulson SK
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):950-958. PubMed ID: 33661566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study.
    Samukawa Y; Sata M; Furihata K; Ito T; Ueda N; Ochiai H; Sakai S; Kumagai Y
    Clin Pharmacol Drug Dev; 2017 Sep; 6(5):439-447. PubMed ID: 28783873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment.
    Hoover R; Marbury TC; Preston RA; Quintas M; Lawrence LE; Paulson SK; Luke DR; Cammarata SK
    J Clin Pharmacol; 2017 Mar; 57(3):328-335. PubMed ID: 27570245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Tolerability of Lorcaserin in Special Populations: Elderly Patients and Patients with Renal or Hepatic Impairment.
    Christopher RJ; Morgan ME; Tang Y; Anderson C; Sanchez M; Shanahan W
    Clin Ther; 2017 Apr; 39(4):837-848.e7. PubMed ID: 28365033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
    Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
    Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study
.
    Shakeri-Nejad K; Aslanis V; Veldandi UK; Gardin A; Zaehringer A; Dodman A; Su Z; Legangneux E
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):41-53. PubMed ID: 27443658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment.
    Wang J; Wang X; Zhang ZY; Arora S; Lu S; Kansra V
    J Clin Pharmacol; 2018 May; 58(5):686-693. PubMed ID: 29329482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function.
    Yin W; Mitra P; Copalu V; Marbury TC; Rondon JC; Lawitz EJ; Lloyd V; Baratta M; Asgharnejad M; Hui T; Khan Y
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1213. PubMed ID: 38993008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
    Glund S; Stangier J; van Ryn J; Schmohl M; Moschetti V; Haazen W; De Smet M; Gansser D; Norris S; Lang B; Reilly P; Kreuzer J
    Clin Pharmacokinet; 2017 Jan; 56(1):41-54. PubMed ID: 27317414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
.
    Gardin A; Dodman A; Kalluri S; Neelakantham S; Tan X; Legangneux E; Shakeri-Nejad K
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):54-65. PubMed ID: 27841151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of nifedipine GITS/candesartan fixed-dose combination in subjects with hepatic impairment
.
    Liu Y; Boettcher MF; Schmidt A; Unger S; Halabi A; Brendel E; Blode H
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):246-255. PubMed ID: 28025965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, Pharmacokinetics and Pharmacodynamics of TNHH, a Novel Targeted Neutrophil-Inhibitory Hirulog Hybrid Glycoprotein, in Healthy Volunteers.
    Gou ZP; Song ZH; Chen XG; Hu XC; Wang Y; Fan K; Cai YM; Zheng L
    CNS Drugs; 2019 Jun; 33(6):605-614. PubMed ID: 31093952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.
    Chattopadhyay N; Riecke K; Ligges S; Zimmermann T; Halabi A; Schultze-Mosgau MH
    Br J Clin Pharmacol; 2019 Sep; 85(9):2011-2021. PubMed ID: 31112623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.